Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

GoPro, Krispy Kreme, and Kohl’s surge as meme stock mania returns. Retail traders drive volatility in a high-liquidity, ...

The company reported second-quarter earnings per share of $1.37, beating the analyst consensus estimate of $1.34. Quarterly sales of $6.962 billion missed the Street view of $6.979 billion.

Pfizer witnessed a dramatic 45.77% surge in trading volume, reaching a staggering 11.97 billion shares. Pfizer's stock price ...

The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial growth in the dysmenorrhea ...

Amgen saw its price target boosted from $315 to $326 by UBS Group, maintaining a neutral stance. This upgrade reflects a ...